Skip to NavigationSkip to content

OxyContin

Judge overseeing Purdue Pharma bankruptcy approves $1.3 million bonus for CEO

Purdue Pharma’s CEO Craig Landau can receive a $1.3 million bonus, ruled a judge.

Judge Robert Drain said the company was justified in giving Landau the bonus as it would keep him as CEO of the company.

Connecticut and the 23 other non-consenting states who have not agreed to settlement terms with Purdue, had strongly opposed the bonus.

Pharmacies argue that prescribers bear ultimate responsibility for the opioid crisis

Pharmacy chains have argued in federal court that doctors and healthcare practitioners who write prescriptions bear ultimate responsibility for the improper distribution of opioids to patients, not the chains themselves.

The filings were submitted Monday to the federal judge in Cleveland, who has been overseeing national opioid lawsuits. It asked the judge to rule in their favour and reject the claims bought by Ohio county against them.

FDA fuelled opioid crisis by failing to police pharmaceutical companies, new study shows

The FDA’s Risk Evaluation and Mitigation Strategy (REMS), which began in 2012, failed to successfully police the companies creating opioids like Oxycontin, a new study shows.

On Monday, Jama Internal Medicine published a report based on a review of more than 9,700 pages of FDA documents pertaining to REMS.

Sackler family withdrew $10 billion from Purdue Pharma while legal pressure mounted, audit shows

An audit commissioned by Purdue Pharma, to help navigate its bankruptcy, indicates that members of the Sackler family withdrew $10.7 billion from the company and distributed it amongst its trusts and overseas holding companies, according to reporting by The New York Times.

Opioid drugmaker Purdue Pharma files for bankruptcy

OxyContin

In the face of thousands of lawsuits in its role in the opioid addiction crisis, Purdue Pharma   announced yesterday that it has filed for bankruptcy, stating funds would go to the 24 states and thousands of cities and counties that are seeking damages from the sale of its opioid painkiller drug OxyContin.

Steve Miller, Chairman of the company’s board of directors, said in a statement: “This unique framework for a comprehensive resolution will dedicate all of the assets and resources of Purdue for the benefit of the American public.

Sacklers could give up Purdue Pharma and settle 2,000 lawsuits for $10-12 billion, proposal says

The Sackler family are offering to settle more than 2,000 opioid crisis lawsuits for between $10-12 billion, according to NBC.

Sackler family lawyers said in a confidential meeting in Cleveland on 20 August that the family would settle lawsuits brought about by states, cities and counties for a sum of between $10 billion and $12 billion.

Sacklers file motion to throw lawsuit out of court

Members of the Sackler family have asked a judge to throw a lawsuit – filed by Massachusetts attorney general Maura Healey – out of court.

The Sacklers, who claim the lawsuit contains “misleading and inflammatory allegations,” argued that Healey’s suit had mischaracterised internal records as part of an effort to create the “false impression” that the Sacklers themselves had directed Purdue Pharma’s marketing of the opioid painkiller OxyContin.

Sacklers fraudulently transferred funds to dodge litigation, lawsuit says

New York state prosecutors have filed a lawsuit against members of the Sackler family, alleging the Purdue Pharma controllers fraudulently transferred hundreds of millions of dollars into offshore accounts, as part of an effort to protect their funds from litigation.

Purdue Pharma settle Oklahoma lawsuit for $270 million

OxyContin drugmaker Purdue Pharma has agreed to pay nearly $270 million to the state of Oklahoma, in order to settle a case brought about by the Oklahoma Attorney General over the company’s role in the opioid crisis.

The case launched by Oklahoma Attorney General Mike Hunter, is the first to be settled after Hunter launched a series of lawsuits against Purdue, Johnson & Johnson, and Teva in 2017.

Tate art galleries will not accept donations from Sacklers

Image Credit: Hpschaefer

The Tate network of art galleries has said it will no longer accept gifts from the notorious Sackler family, the billionaire controllers of OxyContin drugmaker Purdue Pharma.

The decision comes after the National Portrait Gallery turned down a £1 million gift from the Sackler’s who are accused of playing a fundamental role in the opioid epidemic. The backlash follows protests from photographer Nan Goldin.

Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches